• BEAMTREE AGREES NEW GLOBAL CONTRACT WITH ABBOTT
• CONTRACT TO DISTRIBUTE BEAMTREE'S RIPPLEDOWN® PRODUCTS
• EXPECTS AGREEMENT TO BE A MATERIAL CONTRIBUTION TO ITS TOTAL REVENUE
• ABBOTT RETAINS EXCLUSIVE DISTRIBUTION RIGHTS, EXCEPT FOR A SINGLE EXISTING DISTRIBUTION AGREEMENT

The kicker in the (clarified) announcement - Beamtree forecasts between 50 – 100 annual recurring large customer licences by the end of

the three-year term, each with a minimum annual value of USD$300,000.

Following on from @Hogajo's post, this looks like another smart acquisition from the management team. It's early days, but they seem to be building some cred in this area, not too long after the Pavilion Health acquisition, both of which were conducted at reasonable prices, have a high degree of complimentarity, and retain the management teams of the target.

I have decided to hold on to my shares (first acquired at 17c when RippleDown was the only offering in their stable) and see where Tim Kelsey and co. take it, though I have toyed with selling down pre-announcement.